ArticleBMC cardiovascular disorders2026
Development and temporal validation of a two-stage ECG-based machine learning model for LVEF screening: a Middle Eastern cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure is a global health burden, yet artificial intelligence (AI) screening tools for left ventricular ejection fraction (LVEF) have largely been validated in Western populations with limited data from the Middle East. We aimed to develop and validate an interpretable-first, two-stage ECG-based machine learning pipeline to screen for reduced LVEF (Stage 1) and stratify its severity (Stage 2) in a large, diverse Middle Eastern cohort.
methodsWe conducted a retrospective study of 37,233 unique patients from a quaternary-care center in the United Arab Emirates (UAE). The cohort was split into a development set (n = 29,108; 2015–2023) and an independent temporal validation set (n = 8,125; 2024–2025). Stage 1 utilized a logistic regression model to screen for any reduced LVEF (< 52% in men, < 54% in women). Stage 2 applied an XGBoost classifier to positive screens to grade severity as mild (LVEF 41–51% in men, 41–53% in women), moderate (30–40%), or severe (< 30%).
resultsReduced LVEF was present in 18.0% of the overall cohort (17.5% of the development set and 18.6% of the validation set. In the validation cohort, Stage 1 achieved an AUC of 0.82 (95% CI 0.81–0.83) with sensitivity 84% (95% CI 82–86%), specificity 80% (95% CI 78–81%), negative predictive value 91% (95% CI 90–93%), and positive predictive value 68% (95% CI 66–70%). Stage 2 attained 72% overall accuracy; recall for mild, moderate, and severe dysfunction was 74%, 71%, and 72%, respectively, mirroring performance in the internal test set.
conclusionThis two-stage AI-ECG workflow provides an interpretable-first and robust method for heart failure screening in a non-Western population. With a high NPV and temporal stability, the model effectively rules out disease and triages severity, offering a scalable “ECG-first” strategy to prioritize echocardiography resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.